


New York Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in New York from January 2017 through December 2017.

Key New York Findings



Rejection Rate:

27%



Appeals Rate:

34%



Final Rejections:

4,249

Of health plans that received at least 350 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Fidelis Care NY **43%**
- Express Scripts **34%**
- United Health Group **34%**
- Independent Health **25%**

The following had **the lowest rates of rejection:**

- Aetna **12%**
- Humana Health Plan **9%**



The following table details claims data for the New York managed care organizations that received at least 350 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Fidelis Care NY	43%	709	305
United Health Group	34%	2,283	785
Express Scripts	34%	1,085	364
Independent Health	25%	422	104
CVS Health	23%	2,309	528
Healthfirst	20%	433	85
Excellus Health Plan	18%	856	152
Cigna Healthcare	15%	618	95
Aetna	12%	1,597	195
Humana Health Plan	9%	869	81

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

